Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study

UK Collaborative HIV Cohort (CHIC) Study, Andrew N Phillips, Clifford Leen, Alan Wilson, Jane Anderson, David Dunn, Achim Schwenk, Chloe Orkin, Teresa Hill, Martin Fisher, John Walsh, Deenan Pillay, Loveleen Bansi, Brian Gazzard, Philippa Easterbrook, Richard Gilson, Margaret Johnson, Caroline A Sabin

Research output: Contribution to journalArticlepeer-review

Abstract

The long-term durability of viral-load suppression provided by the three original antiretroviral drugs is not well characterised. We estimated the proportion of patients who had extensive triple-class failure during long-term follow-up and examined characteristics associated with an increased rate of failure.
Original languageEnglish
Pages (from-to)1923-8
Number of pages6
JournalThe Lancet
Volume370
Issue number9603
DOIs
Publication statusPublished - 8 Dec 2007

Keywords / Materials (for Non-textual outputs)

  • Adult
  • Anti-Retroviral Agents
  • Antiretroviral Therapy, Highly Active
  • CD4 Lymphocyte Count
  • Cohort Studies
  • Female
  • Follow-Up Studies
  • Great Britain
  • HIV Infections
  • Humans
  • Male
  • Reverse Transcriptase Inhibitors
  • Treatment Failure
  • Viral Load

Fingerprint

Dive into the research topics of 'Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study'. Together they form a unique fingerprint.

Cite this